Compare EML & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EML | ANIX |
|---|---|---|
| Founded | 1858 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.9M | 119.8M |
| IPO Year | 1995 | 2013 |
| Metric | EML | ANIX |
|---|---|---|
| Price | $25.55 | $3.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 9.0K | ★ 194.0K |
| Earning Date | 05-12-2026 | 05-27-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | ★ 185.40 | 12.82 |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $248,970,345.00 | $210,000.00 |
| Revenue This Year | $19.05 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $2.32 |
| 52 Week High | $29.91 | $5.46 |
| Indicator | EML | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 63.08 |
| Support Level | N/A | $2.73 |
| Resistance Level | N/A | $3.89 |
| Average True Range (ATR) | 0.00 | 0.18 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 97.18 |
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to the industrial market. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It has one reportable segment: Engineered Solutions, which provides engineered solutions mainly for the commercial transportation and logistics markets. This segment offers a diverse product line of custom and standard vehicular and industrial hardware, including turnkey returnable packaging solutions, blow molds, compression latches, draw latches, hinges, camlocksaccess, mirrors, and mirror-cameras, among other products. Geographically, the group derives maximum revenue from the United States.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.